A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with B‐cell non‐Hodgkin lymphoma (B‐NHL) or chronic lymphocytic leukaem...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Haematol
Glavni autori: Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Haematological Malignancy
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412890/
https://ncbi.nlm.nih.gov/pubmed/28220479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14534
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items